These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma. Iwai T; Yoshimura M; Ashida R; Goto Y; Kishi T; Itasaka S; Shibuya K; Kanai M; Masui T; Fukuda A; Isoda H; Hiraoka M; Mizowaki T Radiat Oncol; 2020 Nov; 15(1):264. PubMed ID: 33187523 [TBL] [Abstract][Full Text] [Related]
7. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study. Lewis S; Sastri SC; Arya S; Mehta S; Patil P; Shrivastava S; Phurailatpam R; Shrikhande SV; Engineer R J Gastrointest Oncol; 2019 Jun; 10(3):474-482. PubMed ID: 31183197 [TBL] [Abstract][Full Text] [Related]
8. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844 [TBL] [Abstract][Full Text] [Related]
9. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605 [TBL] [Abstract][Full Text] [Related]
10. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Argiris A; Bauman JE; Ohr J; Gooding WE; Heron DE; Duvvuri U; Kubicek GJ; Posluszny DM; Vassilakopoulou M; Kim S; Grandis JR; Johnson JT; Gibson MK; Clump DA; Flaherty JT; Chiosea SI; Branstetter B; Ferris RL Ann Oncol; 2016 Aug; 27(8):1594-600. PubMed ID: 27177865 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT. Jensen AD; Krauss J; Potthoff K; Desta A; Habl G; Mavtratzas A; Windemuth-Kiesselbach C; Debus J; Münter MW BMC Cancer; 2011 May; 11():182. PubMed ID: 21595970 [TBL] [Abstract][Full Text] [Related]
12. A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. Chakravarthy AB; Tsai CJ; O'Brien N; Lockhart AC; Chan E; Parikh A; Berlin JD; Merchant N Gastrointest Cancer Res; 2012 Jul; 5(4):112-8. PubMed ID: 23077684 [TBL] [Abstract][Full Text] [Related]
13. Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer. Shi Z; Yang J; Kong W; Qiu X; Lu C; Liu J; Liu B; Du J Front Oncol; 2022; 12():782730. PubMed ID: 35299738 [TBL] [Abstract][Full Text] [Related]
14. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. Suntharalingam M; Winter K; Ilson D; Dicker AP; Kachnic L; Konski A; Chakravarthy AB; Anker CJ; Thakrar H; Horiba N; Dubey A; Greenberger JS; Raben A; Giguere J; Roof K; Videtic G; Pollock J; Safran H; Crane CH JAMA Oncol; 2017 Nov; 3(11):1520-1528. PubMed ID: 28687830 [TBL] [Abstract][Full Text] [Related]
15. Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. Rossi G; Simoni N; Paiella S; Rossi R; Venezia M; Micera R; Malleo G; Salvia R; Giuliani T; Di Gioia A; Auriemma A; Milella M; Guariglia S; Cavedon C; Bassi C; Mazzarotto R Front Oncol; 2021; 11():662205. PubMed ID: 33959509 [TBL] [Abstract][Full Text] [Related]
16. Randomized controlled study comparing simultaneous modulated accelerated radiotherapy versus simultaneous integrated boost intensity modulated radiotherapy in the treatment of locally advanced head and neck cancer. Tandon S; Gairola M; Ahlawat P; Rawat S; Aggarwal A; Sharma K; Tiwari S; Karimi AM; Muttagi V; Sachdeva N; Bhushan M J Egypt Natl Canc Inst; 2018 Sep; 30(3):107-115. PubMed ID: 29960876 [TBL] [Abstract][Full Text] [Related]
17. A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer. Sanghvi SM; Coffman AR; Hsueh CT; Kang J; Park A; Solomon NL; Garberoglio CA; Reeves ME; Slater JD; Yang GY J Gastrointest Oncol; 2022 Aug; 13(4):1989-1996. PubMed ID: 36092320 [TBL] [Abstract][Full Text] [Related]
18. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M; Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206 [TBL] [Abstract][Full Text] [Related]
19. Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating. van den Heuvel MM; Uyterlinde W; Vincent AD; de Jong J; Aerts J; Koppe F; Knegjens J; Codrington H; Kunst PW; Dieleman E; Verheij M; Belderbos J Radiother Oncol; 2014 Jan; 110(1):126-31. PubMed ID: 24225233 [TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiation therapy for locally advanced pancreatic cancer. Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]